Evolus, Inc. (EOLS) NASDAQ
6.17
-0.35(-5.37%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
6.17
-0.35(-5.37%)
Currency In USD
Address
520 Newport Center Drive
Newport Beach, CA 92660
United States of America (the)
Phone
949 284 4555
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
372
First IPO Date
February 08, 2018
| Name | Title | Pay | Year Born |
| David Moatazedi | President, Chief Executive Officer & Director | 1.23M | 1978 |
| Tomoko Yamagishi-Dressler | Chief Marketing Officer | 677,374 | 1965 |
| Tatjana Mitchell | Chief Financial Officer | 711,398 | N/A |
| Rui Avelar C.CFP Dip.SportMed | Chief Medical Officer and Head of Research & Development | 730,167 | 1962 |
| Jeffrey J. Plumer | Corporate Secretary | 0 | N/A |
| Nareg Sagherian | Head of Global Investor Relations & Corporate Communications | 0 | N/A |
| Kurt Knab | Senior Vice President of Sales | 0 | N/A |
| Jessica Novak | Senior Vice President of Human Resources | 0 | N/A |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.